The Relationship Between COMT and MAO-B Gene Polymorphisms with Levodopa in Parkinson’s Disease Patients; A Review

Vina Luthfiana Hasna, Ahsanal Kasasiah, Rosario Trijuliamos Manalu, Jekmal Malau

Abstract


Parkinson's disease is a degenerative nervous system disorder caused by the death of dopamine-producing cells in the substantia nigra. Dopaminergic treatment could alleviate motor symptoms for a period. One of the effective dopaminergic medications for symptomatic relief was Levodopa and dopamine agonists. Clinically, Levodopa was always combined with Dopa Decarboxylase (DDC) inhibitors, which redirected Levodopa metabolism towards the COMT pathway, increasing its bioavailability in the central nervous system. The purpose of this article was to investigate the relationship between COMT and MAO-B gene polymorphisms and Levodopa in Parkinson's disease patients, starting by gathering literature on the association between COMT and MAO-B polymorphisms and Levodopa in Parkinson's disease patients using various databases. Reviewed literature revealed that the most frequent polymorphism in the COMT gene was rs4680. Some polymorphisms significantly impacted the treatment of Parkinson's disease patients. However, despite efforts to identify genetic factors influencing the risk of side effects or treatment ineffectiveness, the role of pharmacogenetics in Parkinson's disease has not been fully explored and lacks consistent clinical recommendations. Further research was needed to tailor treatment to individual polymorphisms so that pharmacogenomic approaches could be applied more consistently

Keywords


DNA Polymorphism, Levodopa, Pharmacogenomic

Full Text:

PDF

References


Aldred, J., and J. G. Nutt. 2010. “Levodopa.” Pp. 132–37 in Encyclopedia of Movement Disorders. Elsevier.

Cheshire, Perdita, Kelly Bertram, Helen Ling, Sean S. O’Sullivan, Glenda Halliday, Catriona McLean, Jose Bras, Tom Foltynie, Elsdon Storey, and David R. Williams. 2014. “Influence of Single Nucleotide Polymorphisms in COMT, MAO-A and BDNF Genes on Dyskinesias and Levodopa Use in Parkinson’s Disease.” Neurodegenerative Diseases 13(1):24–28. doi: 10.1159/000351097.

Chuan, Lixue, Jie Gao, Yuying Lei, Raoxiang Wang, Lechun Lu, and Xianyu Zhang. 2015. “Val158Met Polymorphism of COMT Gene and Parkinson’s Disease Risk in Asians.” Neurological Sciences 36(1):109–15. doi: 10.1007/s10072-014-1896-0.

Cui, Shi-Shuang, Ling-Yu Wu, Gen Li, Juan-Juan Du, Pei Huang, Jin Liu, Yun Ling, Kang Ren, Zhong-Lue Chen, and Sheng-Di Chen. 2022. “MAO-B Polymorphism Associated with Progression in a Chinese Parkinson’s Disease Cohort but Not in the PPMI Cohort.” Parkinson’s Disease 2022:1–8. doi: 10.1155/2022/3481102.

Dietrichs, E., and P. Odin. 2017. “Algorithms for the Treatment of Motor Problems in Parkinson’s Disease.” Acta Neurologica Scandinavica 136(5):378–85. doi: 10.1111/ane.12733.

Droździk, Marek, Monika Białecka, and Mateusz Kurzawski. 2013. “Pharmacogenetics of Parkinson’s Disease - through Mechanisms of Drug Actions.” Current Genomics 14(8):568–77. doi: 10.2174/1389202914666131210212521.

Elroby, Shabaan A. K., Mohamed S. I. Makki, Tariq R. Sobahi, and Rifaat H. Hilal. 2012. “Toward the Understanding of the Metabolism of Levodopa I. DFT Investigation of the Equilibrium Geometries, Acid-Base Properties and Levodopa-Water Complexes.” International Journal of Molecular Sciences 13(4):4321–39. doi: 10.3390/ijms13044321.

Fan, Xiaoyan, Lixia Zhang, Haijun Li, Guang Chen, Gangqiao Qi, Xueqiang Ma, and Yuelei Jin. 2020. “Role of Homocysteine in the Development and Progression of Parkinson’s Disease.” Annals of Clinical and Translational Neurology 7(11):2332–38. doi: 10.1002/acn3.51227.

Hanson, M. R., and N. Gálvez-Jiménez. 2001. “Catechol-O-Methyltransferase Inhibitors in the Management of Parkinson’s Disease.” Seminars in Neurology 21(1):15–22.

Ivanova, Svetlana A., Valentina M. Alifirova, Ivan V Pozhidaev, Maxim B. Freidin, Irina A. Zhukova, Diana Z. Osmanova, Natalia G. Zhukova, Yulia A. Mironova, Vladimir V Tiguntsev, Olga Yu Fedorenko, Nikolay A. Bokhan, Bob Wilffert, and Anton J. M. Loonen. 2018. Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia. Vol. 21.

Jenner, Peter, José-Francisco Rocha, Joaquim J. Ferreira, Olivier Rascol, and Patrício Soares-da-Silva. 2021. “Redefining the Strategy for the Use of COMT Inhibitors in Parkinson’s Disease: The Role of Opicapone.” Expert Review of Neurotherapeutics 21(9):1019–33. doi: 10.1080/14737175.2021.1968298.

De Lau, Lonneke M. L., Dagmar Verbaan, Johan Marinus, Peter Heutink, and Jacobus J. Van Hilten. 2012. “Catechol-O-Methyltransferase Val158Met and the Risk of Dyskinesias in Parkinson’s Disease.” Movement Disorders 27(1):132–35. doi: 10.1002/mds.23805.

Löhle, Matthias, Graziella Mangone, Wiebke Hermann, Denise Hausbrand, Martin Wolz, Julia Mende, Heinz Reichmann, Andreas Hermann, Jean-Christophe Corvol, and Alexander Storch. 2022. “Functional MAOB Gene Intron 13 Polymorphism Predicts Dyskinesia in Parkinson’s Disease.” Parkinson’s Disease 2022:5597503. Doi: 10.1155/2022/5597503.

Lotankar, Sharvari, Kedar S. Prabhavalkar, and Lokesh K. Bhatt. 2017. “Biomarkers for Parkinson’s Disease: Recent Advancement.” Neuroscience Bulletin 33(5):585–97. doi: 10.1007/s12264-017-0183-5.

Michałowska, Małgorzata, Małgorzata Chalimoniuk, Ewa Jówko, Iwona Przybylska, Józef Langfort, Beata Toczylowska, Anna Krygowska-Wajs, and Urszula Fiszer. 2020. “Gene Polymorphisms and Motor Levodopa-Induced Complications in Parkinson’s Disease.” Brain and Behavior 10(3):e01537. doi: 10.1002/brb3.1537.

Ng, Jeffrey Sheung Ching. 2018. “Palliative Care for Parkinson’s Disease.” Annals of Palliative Medicine 7(3):296–303. doi: 10.21037/apm.2017.12.02.

Opara, Józef, Andrzej Małecki, Elżbieta Małecka, and Teresa Socha. 2017. “Motor Assessment in Parkinson`s Disease.” Annals of Agricultural and Environmental Medicine 24(3):411–15. doi: 10.5604/12321966.1232774.

Sampaio, Tiago Furtado, Erinaldo Ubirajara Damasceno dos Santos, Gessica Dayane Cordeiro de Lima, Rute Salgues Gueiros dos Anjos, Ronaldo Celerino da Silva, Amdore Guescel C. Asano, Nadja Maria Jorge Asano, Sergio Crovella, and Paulo Roberto Eleutério de Souza. 2018. “MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson’s Disease.” Journal of Clinical Pharmacology 58(7):920–26. doi: 10.1002/jcph.1096.

dos Santos, Erinaldo Ubirajara Damasceno, Isaura Isabelle Fonseca Gomes da Silva, Amdore Guescel C. Asano, Nadja Maria Jorge Asano, Maria De Mascena Diniz Maia, and Paulo Roberto Eleutério de Souza. 2020. “Pharmacogenetic Profile and the Development of the Dyskinesia Induced by Levodopa-Therapy in Parkinson’s Disease Patients: A Population-Based Cohort Study.” Molecular Biology Reports 47(11):8997–9004. doi: 10.1007/s11033-020-05956-9.

Setiarini, Rohmania, and Subagya. 2018. “Profil Pasien Parkinson Di Poliklinik Saraf RSUP Dr. Sardjito.” 169–75.

Tolosa, Eduardo, Alicia Garrido, Sonja W. Scholz, and Werner Poewe. 2021. “Challenges in the Diagnosis of Parkinson’s Disease.” The Lancet. Neurology 20(5):385–97. doi: 10.1016/S1474-4422(21)00030-2.

Vuletić, Vladimira, Valentino Rački, Eliša Papić, and Borut Peterlin. 2021. “A Systematic Review of Parkinson’s Disease Pharmacogenomics: Is There Time for Translation into the Clinics?” International Journal of Molecular Sciences 22(13). doi: 10.3390/ijms22137213.

Yamamoto, Joe, Tomohiro Omura, Sachiko Kasamo, Shota Yamamoto, Masayoshi Kawata, Atsushi Yonezawa, Yosuke Taruno, Hisako Endo, Hitoshi Aizawa, Nobukatsu Sawamoto, Kazuo Matsubara, Ryosuke Takahashi, and Yoshikazu Tasaki. 2021. “Impact of the Catechol-O-Methyltransferase Val158Met Polymorphism on the Pharmacokinetics of l-Dopa and Its Metabolite 3-O-Methyldopa in Combination with Entacapone.” Journal of Neural Transmission 128(1):27–36. doi: 10.1007/s00702-020-02267-y.




DOI: https://doi.org/10.36987/jpbn.v10i1.5228

Refbacks

  • There are currently no refbacks.


Copyright (c) 2024 Vina Luthfiana Hasna, Ahsanal Kasasiah, Rosario Trijuliamos Manalu, Jekmal Malau

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

 

 

 

 

 

 

 

 

 

 

 

Lisensi Creative Commons

Jurnal Pembelajaran dan Biologi Nukleus by LPPM Universitas Labuhanbatu is under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY - NC - SA 4.0)